Russell Read is an Ophthalmology physician affiliated with University of Alabama at Birmingham. OpenAlex indexes 129 publications with 5,258 citations (h-index 37).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
700 18th St S Ste 601
Birmingham, AL 352333800
Telephone
205-325-8620Provider last certified this registry record 18 Aug 2020.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Johnson & Johnson Surgical Vision, Inc.Program year20212 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
60.4%Carbonic Anhydrase Inhibitor21.8%Dorzolamide-Timolol52%Dorzolamide Hcl39%Brinzolamide6%Simbrinza3%Part D<11 patientsCorticosteroid18.9%Prednisolone Acetate100%Part D≥155 patients+ 3 more classes in this area
Musculoskeletal
11.4%Cyclooxygenase Inhibitor11.4%Ketorolac Tromethamine100%Part D≥81 patientsMetabolism & gastrointestinal
9.1%Corticosteroid7%Prednisone100%Part D≥47 patientsAnticholinergic1.4%Atropine Sulfate100%Part D≥19 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2002–2006 per NIH RePORTER. The latest:
- Complement inhibition in experimental autoimmune uveitis
University of Alabama at Birmingham
FY2006$209,374K08EY014189 - Complement inhibition in experimental autoimmune uveitis
University of Alabama at Birmingham
FY2005$202,360K08EY014189 - Complement inhibition in experimental autoimmune uveitis
University of Alabama at Birmingham
FY2004$195,615K08EY014189
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Subretinal Pigment Epithelial Deposition of Drusen Components Including Hydroxyapatite in a Primary Cell Culture Model
Investigative Ophthalmology & Visual Science
2017
Similar KOLs
Other experts from the same institution or the same specialty.
Vera Bittner
University of Alabama at Birmingham
Richard Whitley, MD
University of Alabama at Birmingham
David Standaert, MD, PhD
University of Alabama at Birmingham
Erik Roberson
University of Alabama at Birmingham
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”